TY - JOUR
T1 - Lymphoma in inflammatory bowel disease
T2 - Baseline risk and influence of immunomodulators
AU - Loftus, E. V.
PY - 2002
Y1 - 2002
N2 - There has been controversy over whether inflammatory bowel disease (IBD) patients are at increased risk of developing malignant lymphoma relative to the general population. Large population-based studies from several locales have shown that there is not an increased risk of lymphoma in IBD compared to the general population, with two exceptions. Some but not all referral- or hospital-based studies have suggested an increased baseline risk of lymphoma in IBD; however, these studies must be discounted because referral bias may have influenced the results. The bulk of the evidence suggests no increased baseline risk of lymphoma in IBD. Although several case series have detected a low frequency of lymphoma in IBD patients receiving purine analogues, one series reported a markedly increased risk among those treated with azathioprine, methotrexate and cyclosporin. Moreover, there are several reports of Epstein-Barr virus-positive lymphomas, which are likely related to immunosuppression, occurring in patients receiving these medications. Whether immunomodulatory medications are associated with an increased risk of lymphoma in IBD remains unclear.
AB - There has been controversy over whether inflammatory bowel disease (IBD) patients are at increased risk of developing malignant lymphoma relative to the general population. Large population-based studies from several locales have shown that there is not an increased risk of lymphoma in IBD compared to the general population, with two exceptions. Some but not all referral- or hospital-based studies have suggested an increased baseline risk of lymphoma in IBD; however, these studies must be discounted because referral bias may have influenced the results. The bulk of the evidence suggests no increased baseline risk of lymphoma in IBD. Although several case series have detected a low frequency of lymphoma in IBD patients receiving purine analogues, one series reported a markedly increased risk among those treated with azathioprine, methotrexate and cyclosporin. Moreover, there are several reports of Epstein-Barr virus-positive lymphomas, which are likely related to immunosuppression, occurring in patients receiving these medications. Whether immunomodulatory medications are associated with an increased risk of lymphoma in IBD remains unclear.
UR - http://www.scopus.com/inward/record.url?scp=0036265274&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036265274&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0036265274
SN - 0143-3083
VL - 24
SP - 45
EP - 49
JO - Research and Clinical Forums
JF - Research and Clinical Forums
IS - 1
ER -